Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines

Inclusion Criteria: * Patients who agree with all study procedures and sign for their own free will the TCLE; * Adult patients were female between 18 and 65 years, regardless of social condition; * between skin phototype I and IV; * With good mental and physical health; * Patients who have not been treated with botulinum toxin type A; * Patients who agree to abstain from physical activity for a period of 24 hours, previous and subsequent to the initiation of the study; * Patients presenting at screening visit, wrinkles in the glabellar region between classes 2 and 3 of Table Wrinkles Pattern Classification, which is diagnosed clinically by the dermatologist. Exclusion Criteria: * Patients who are in classes 0 and 1 of the Table Pattern Classification Wrinkle; * Patients who have disorders or diseases that might interfere with neuromuscular function (myasthenia gravis or Lambert-Eaton syndrome); * Patients being treated with antibiotics (aminoglycosides) and muscle relaxants; * Patients with pre-existing conditions such as ptosis or scars in the area to be assessed, as they may endanger the health of the patient and the results of the study; * Patients who have made treatments fill in the glabellar region (retinoic acid, collagen); * Patients who have been treated in the dermatological peeling úlitmos three months; * Patients are using treatments dermacosmetics agents anti age (vitamin C pure retinoids flavanoids acid hyaluronic others) or used past 3 months * Patients with known hypersensitivity to any component of the study drug; * Pregnant or lactating women;